Compounded drug market needs transparency, more regulatory certainty, says Pew

Healthcare Finance News June 29, 2020
Jeff Lagasse

Providers, compounders, individual states and the FDA all have roles to play in stemming drug shortages during the pandemic.

Even before the COVID-19 pandemic began to grip the country, many health system administrators found it difficult to procure specific drugs from outsourcing facilities, the FDA-registered compounders authorized to make office stock medications under federal law.

While the pandemic has made drug shortages worse across the U.S., pre-existing supply chain issues were already both prevalent and deep-rooted.

Before the coronavirus fundamentally affected American life and the healthcare system, Pew Charitable Trusts conducted interviews with representatives from six outsourcing facilities to understand what might be causing these challenges. Four themes emerged.

For one, challenges specific to certain drugs can ramp up...

Today's Sponsors

Today's Sponsor